Serina Therapeutics SER 深 沪
交易中 09-25 11:37:42 美东时间
2.12
-0.020
-0.93%
华盛通- 最 高2.19
- 今 开2.17
- 成交量 1.82万股
- 最 低 2.0901
- 昨 收 2.14
- 总市值 5384.90万
- 52周最高 5.83
- 市盈率 静 --
- 换手率 0.07%
- 52周最低 1.22
- 委 比 -1.08%
- 总股本 2540.05万
- 历史最高 209.2615
- 量 比 1.69
- 振 幅 4.67%
- 历史最低 1.22
- 每 手 1
- 风险率 1.09%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 齐声看好医药股！礼来、强生、默沙东目标价均获上调；小摩大幅上调Meta目标价至820美元
今日重点评级关注：康托·菲茨杰拉德：维持SOL Strategies"超配"评级，目标价从2.8美元升至6.2美元；康托·菲茨杰拉德：维持Sui Group Holdings"超配"评级，目标价从1.7美元升至3.4美元
09-11 14:30
BTIG Reiterates Buy on Serina Therapeutics, Maintains $8 Price Target
BTIG analyst Thomas Shrader reiterates Serina Therapeutics (AMEX:SER) with a Buy and maintains $8 price target.
09-10 23:27
Serina Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Serina Therapeutics, a clinical-stage biotechnology company, announced that CEO Steve Ledger will present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14-16, 2026, in New York. The presentation will be available on-demand starting September 14, 2026, at 7:00 a.m. ET. Serina is developing its proprietary POZ Platform™ technology to optimize drug candidates for neurological diseases and other conditions, with its lea...
09-10 20:05
Serina Therapeutics Files Prospectus Related To The Offer And Sale Of Up To 12,500,000 Shares Of Common Stock By Roth Principal Investments
Serina Therapeutics Files Prospectus Related To The Offer And Sale Of Up To 12,500,000 Shares Of Common Stock By Roth Principal Investments
08-25 05:32
Gannet BioChem To Support Development Activities For SER-252, Serina Therapeutics' Investigational Therapy For Advanced Parkinson's Disease
Gannet BioChem, a leading life sciences manufacturing company, today announced a development partnership with Serina Therapeutics, Inc. (NYSE:SER), a clinical-stage biotechnology company advancing therapies enabled by its proprietary POZ Platform™ technology. Under the agreement, Gannet BioChem will...
06-30 21:08
Serina Therapeutics Files Prospectus For Offering 16.45M Common Shares On Behalf Of Selling Stockholders
https://www.sec.gov/Archives/edgar/data/1708599/000149315226025007/forms-3.htm
05-23 04:04
Serina Therapeutics Says Phase 1b Registrational Clinical Study of SER-252 Underway In Advanced Parkinson's Disease; TFL Data From The SAD Study Arm Targeted For First Half of 2027
SER-252 Phase 1b Registrational Clinical Study: Following dosing of the first patient in February 2026, Serina continues to advance its Phase 1b registrational clinical study of SER-252 in advanced Parkinson's disease.
05-15 05:52
Serina Therapeutics Q1 EPS $(0.58) Misses $(0.44) Estimate
Serina Therapeutics (AMEX:SER) reported quarterly losses of $(0.58) per share which missed the analyst consensus estimate of $(0.44) by 31.82 percent. This is a 18.37 percent decrease over losses of $(0.49) per share
05-15 04:43
